Evidence map›Paper›PMID 32958684›Full record

ArticleJournal for immunotherapy of cancer2020

Malignant cell-specific CXCL14 promotes tumor lymphocyte infiltration in oral cavity squamous cell carcinoma.

Anuraag Parikh, JuneHo Shin, William Faquin, Derrick T Lin, Itay Tirosh, John B Sunwoo, Sidharth V Puram

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Translational cancer research · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. CXCL14 regulates ovarian endometriosis progression by targeting PCNA.American journal of translational research · 2025
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Anuraag Parikh *Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.ORCID 0000-0003-0968-1028
JuneHo Shin *Otolaryngology, Stanford University School of Medicine, Stanford, California, USA.
William FaquinPathology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
Derrick T LinOtolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
Itay TiroshDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
John B SunwooOtolaryngology, Stanford University School of Medicine, Stanford, California, USA sidpuram@wustl.edu sunwoo@stanford.edu.
Sidharth V PuramOtolaryngology, Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, USA sidpuram@wustl.edu sunwoo@stanford.edu.
Massachusetts Eye and Ear Infirmary · USStanford University · USWashington University in St. Louis · USWeizmann Institute of Science · IL

Funding

Understanding programs of invasion and metastasis in head and neck cancerK08CA237732 · NCI · WASHINGTON UNIVERSITY · PI PURAM, SIDHARTH VENKATA · 2019 to 2023
$984k
NCI NIH HHS K08 CA237732
6 · The paper itself

Abstract

objectivesTo explore lymphocyte infiltration as a potential mechanism behind CXCL14-mediated tumor growth suppression in oral cavity squamous cell carcinoma (OSCC).

methodsWe analyzed single cell RNA-sequencing (scRNA-seq) data from OSCC to identify expression changes among malignant cells in lymph nodes (LN) versus primary tumors. CXCL14 expression in murine OSCC cell lines was quantified using qRT-PCR. Short hairpin RNA knockdown of CXCL14 was performed in mouse oral cavity (MOC)1 cells, and CXCL14 overexpression was performed in MOC2 cells. Cells in each condition were injected into C57BL/6 mice with and without T cell depletion, and tumor volume was measured. At 30 days, tumors were dissociated and analyzed by flow cytometry for CD45

resultsscRNA-seq revealed CXCL14 as the most significantly downregulated gene among malignant cells in LNs relative to primary tumor, supporting a role in preventing invasion and/or metastasis. In a murine immunocompetent model, CXCL14 expression was higher in indolent MOC1 cells than in more aggressive MOC2 cells. Tumor growth

conclusionsHigher CXCL14 expression by tumor cells is associated with reduced tumor growth and increased TIL, supporting immune-mediated suppression of tumor growth in OSCC. Given that CXCL14 is downregulated in LN metastases compared with primary tumors, our data raise the possibility that CXCL14-mediated immune infiltration may discourage invasion and metastasis. In human scRNA-seq data, only malignant cell-specific CXCL14 was associated with TIL, suggesting a critical context-dependent effect of CXCL14 expression.

Indexed as

Carcinoma, Squamous CellCell ProliferationChemokines, CXCGene Expression ProfilingHumansLymphocytesMouth NeoplasmsChemokines, CXCCXCL14 protein, mousecytokinesgene expression profilinghead and neck neoplasmslymphocytesT-lymphocytestumor-infiltrating

Identifiers

PMID32958684
PMCPMC7507891
OpenAlexW3087349051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.